- Home
- CLLS vs NLSP Comparison
CLLS vs NLSP Comparison
Compare CLLS & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- NLSP
- Stock Information
- Founded
- CLLS 1999
- NLSP 2015
- Country
- CLLS France
- NLSP Switzerland
- Employees
- CLLS N/A
- NLSP N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- NLSP Health Care
- Exchange
- CLLS Nasdaq
- NLSP Nasdaq
- Market Cap
- CLLS 240.2M
- NLSP 243.8M
- IPO Year
- CLLS 2007
- NLSP 2021
- Fundamental
- Price
- CLLS $1.89
- NLSP $4.90
- Analyst Decision
- CLLS Buy
- NLSP
- Analyst Count
- CLLS 2
- NLSP 0
- Target Price
- CLLS $8.00
- NLSP N/A
- AVG Volume (30 Days)
- CLLS 20.5K
- NLSP 25.9K
- Earning Date
- CLLS 11-04-2024
- NLSP 10-11-2024
- Dividend Yield
- CLLS N/A
- NLSP N/A
- EPS Growth
- CLLS N/A
- NLSP N/A
- EPS
- CLLS N/A
- NLSP N/A
- Revenue
- CLLS $19,635,000.00
- NLSP N/A
- Revenue This Year
- CLLS $271.02
- NLSP N/A
- Revenue Next Year
- CLLS $33.48
- NLSP N/A
- P/E Ratio
- CLLS N/A
- NLSP N/A
- Revenue Growth
- CLLS N/A
- NLSP N/A
- 52 Week Low
- CLLS $0.96
- NLSP $4.08
- 52 Week High
- CLLS $3.77
- NLSP $40.60
- Technical
- Relative Strength Index (RSI)
- CLLS 30.12
- NLSP 37.46
- Support Level
- CLLS $1.95
- NLSP $4.72
- Resistance Level
- CLLS $2.08
- NLSP $5.50
- Average True Range (ATR)
- CLLS 0.11
- NLSP 0.65
- MACD
- CLLS -0.04
- NLSP 0.02
- Stochastic Oscillator
- CLLS 0.00
- NLSP 28.47
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.